SavedAdd your journal

Journals / Eurasian Journal of Medical Investigation / 2021 / Cilt: 5 - Sayı: 1

The Importance of Platinum Sensitivity in Metastatic Malignant Pleural Mesothelioma Patients

Erdem ÇUBUKÇU
Birol OCAK
Ahmet Bilgehan ŞAHİN
Adem DELİGÖNÜL
Sibel OYUCU ORHAN
Türkkan EVRENSEL
Turgut KAÇAN
Bahar DAKİKİ
Hikmet Utku ODMAN
Neslihan Hazel SAYDAM
Pages
89–94
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The median overall survival (OS) was found to be 10.5 months (CI 95% 5.8-15.2).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Malignant pleural mesothelioma (MPM) accounts for approximately 80% of all mesothelioma cases.Methods: Forty-three patients diagnosed with advanced MPM were included in our study.
📊
Key Findings & Data:We aimed to investigatefirst-line therapy options and the importance of platinum sensitivity in patients diagnosed with MPM, who were denovo metastatic or progressed from the early to the metastatic stage.Results: The mean age of the patients was 58.8±11.7 years, and 58.1% (25 patients) were male.
💡
Conclusion & Impact:The median overall survival (OS) was found to be 10.5 months (CI 95% 5.8-15.2).
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: Malignant pleural mesothelioma (MPM) accounts for approximately 80% of all mesothelioma cases.Methods: Forty-three patients diagnosed with advanced MPM were included in our study. We aimed to investigatefirst-line therapy options and the importance of platinum sensitivity in patients diagnosed with MPM, who were denovo metastatic or progressed from the early to the metastatic stage.Results: The mean age of the patients was 58.8±11.7 years, and 58.1% (25 patients) were male. The median overall survival (OS) was found to be 10.5 months (CI 95% 5.8-15.2). Median progression-free survival (PFS) of all MPMpatients was 7.6 months (CI 95% 6.2-7.9). When comparing the platinum-sensitive group to the platinum-resistantgroup, the median OS of the platinum-sensitive group was found to be 10.5 months (CI 95% 4.6-16.5), and the median OS of the platinum-resistant group was 3.3 months (CI 95% 3.1-3.6) (p=0.02). The median PFS of the platinumsensitive group was 7.9 months (CI 95% 5.9-9.9), while that for the platinum-resistant group was 2.4 months (CI 95%2.1-2.8) (p

🔖

Cite This Article

ÇUBUKÇU, E., OCAK, B., ŞAHİN, A. B., DELİGÖNÜL, A., ORHAN, S. O., EVRENSEL, T., KAÇAN, T., DAKİKİ, B., ODMAN, H. U., SAYDAM, N. H. (2022). The Importance of Platinum Sensitivity in Metastatic Malignant Pleural Mesothelioma Patients. Eurasian Journal of Medical Investigation, Cilt: 5 - Sayı: 1, 89–94. https://ajindex.com/articles/508615

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. J Occup Med 1992;34:718– 21
  2. Selikoff IJ, Hammond EC, Seidman H. Latency of asbestos disease among insulation workers in the United States and Canada. Cancer 1980;46:2736–40
  3. Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin Oncol 2002;29:2–17
  4. Boutin C, Dumortier P, Rey F, Viallat JR, de Vuyst P. Black spots concentrate oncogenic asbestos fibers in the parietal pleura. Thoracoscopic and mineralogic study. Am J Respir Crit Care Med 1996;153:444–9
  5. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC. World Health Organization Classification of Tumours; 2020. Available at: http://www.iarc.fr/ıarcpress/pdfs/index1.php. Accessed Apr 02, 2020
  6. Kindler HL, Ismaila N, Armato SG 3rd, Bueno R, Hesdorffer M, Jahan T, et al. Treatment of malignant pleural mesothelioma: American society of clinical oncology clinical practice guideline. J Clin Oncol 2018;36:1343–73
  7. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636–44
  8. Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006;24:1443– 8
  9. Pfisterer J, Ledermann JA. Management of platinum-sensitive recurrent ovarian cancer. Semin Oncol 2006;33 Suppl 6:12–6
  10. Hayashi H, Okamoto I, Ichikawa Y, Miyazaki M, Yoshioka H, Kunimasa K, et al. Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed. Int J Clin Oncol 2010;15:497–9
  11. Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008;26:1698–704
  12. Zucali PA, Simonelli M, Michetti G, Tiseo M, Ceresoli GL, Collovà E, et al. Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey. Lung Cancer 2012;75:360–7
  13. Katirtzoglou N, Gkiozos I, Makrilia N, Tsaroucha E, Rapti A, Stratakos G, et al. Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: A Phase II study. Clin Lung Cancer 2010;11:30–5
  14. Zalcman G, M